ENGN
enGene TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The constructive case is that the stock already reflects deep skepticism after the May durability reset, while the company still points to a 2H 2026 BLA plan, completed manufacturing validation batches, and runway into 2H 2028, leaving room for sharp upside if FDA dialogue stays constructive and later LEGEND durability data improve.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Although cash runway appears solid into 2H 2028, ENGN remains a clinical-stage biotech with operating burn and an expanded debt facility, so a prolonged delay could eventually revive financing or dilution concerns [#SEC-8K-2026-03-09].
Momentum
46
Value
57
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.80 · Bull $4.50 · Bear $0.70
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $6.85
Why
Momentum46 · Δ7d +22.0
Value57 · Δ7d -0.1
Sentiment63 · Δ7d -7.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
46
26% active weight
Current posture
7d trendImproving
Δ7d
+22.0
Δ21d
-
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.0
Sentiment
63
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.1
Δ21d
-
Why this grade
Composite grade B. Momentum 46.2 / Value 57.4 / Sentiment 63.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$121.92M
Beta
-0.28
Shares Out
66.99M
P/E (TTM) · Derived
-0.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.97
Rev YoY
-
EPS YoY
-14.3%
Gross Margin
-
Op Margin
-
Net Debt
-$162.02M
Current Ratio
12.57
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology